非小细胞肺癌患者的SCCA水平及其对预后评估的意义

SCCA level in non-small cell lung cancer patients and its prognostic significance

目的检测非小细胞肺癌(NSCLC)患者的鳞状细胞癌抗原(SCCA)水平,探讨SCCA在NSCLC患者预后中的临床价值。方法回顾性分析31例小细胞肺癌(SCLC)患者(SCLC组)和108例NSCLC患者(NSCLC组)的临床资料。应用化学发光免疫分析法检测并比较两组患者的血清SCCA水平及不同临床分期NSCLC患者的血清SCCA水平及阳性率,比较SCCA阳性、阴性NSCLC患者的格拉斯哥预后评分(GPS)和3年生存率。结果NSCLC组鳞癌和腺癌患者的SCCA水平均高于SCLC组,差异均有统计学意义(P﹤0.05);而NSCLC组鳞癌和腺癌患者的SCCA水平比较,差异无统计学意义(P﹥0.05)。Ⅲ～Ⅳ期患者的SCCA水平、阳性率均高于Ⅰ～Ⅱ期患者,差异均有统计学意义(P﹤0.05)。SCCA阳性患者的平均GPS为(1.62±0.37)分,明显低于SCCA阴性患者的(3.15±0.18)分,差异有统计学意义(P﹤0.01);SCCA阳性患者的3年生存率为23.9%,低于SCCA阴性患者的46.3%,差异有统计学意义(P﹤0.05)。结论 NSCLC患者的SCCA水平高于SCLC患者,且NSCLC患者的SCCA水平与临床分期、生存期有关,可能成为NSCLC患者的预后指标。

Objective To detect the level of squamous cell carcinoma antigen (SCCA) in patients with non-small cell lung cancer (NSCLC) and to explore the clinical value of SCCA in predicting the prognosis of NSCLC patients. Method The clinical data of 31 cases with small cell lung cancer (SCLC)(SCLC group) and 108 cases with NSCLC (NSCLC group) were retrospectively analyzed. The serum level of SCCA and the positive rate of SCCA in the two groups of patients and in patients with different clinical stages of NSCLC were detected by chemiluminescent immunoassay, and the Glasgow prognostic score (GPS) in patients with positive and negative SCCA was compared, in addition, the 3-year survival rate was assessed. Result The level of SCCA in squamous cell carcinoma and adenocarcinoma patients with NSCLC was significantly higher than that in those with SCLC (P<0.05);while there was no significant difference in level of SCCA between patients with squamous cell carcinoma and adenocarcinoma in NSCLC group (P>0.05). Patients with stage III-IV disease had significantly higher level of SCCA and positive rate than those with stage I-II lesions, with statistically significant difference observed (P<0.05). The average GPS in patients with positive SCCA was 1.62±0.37, which was significantly lower than that in those with negative SCCA at 3.15±0.18, indicating statistically significant differences (P<0.01);the 3-year survival rate in SCCA-positive patients was 23.9%, and was lower than that in SCCA-negative patients at 46.3%, demonstrating statistically significant difference (P<0.05). Conclusion The level of SCCA in NSCLC is higher than that in SCLC, and it is related to the clinical stage and survival time of the patients with NSCLC, which can be employed as a diagnostic marker for the prognosis of NSCLC patients.